

## BEST OF SABCS CROATIA, Zagreb 20. - 21. February 2026.

### PROGRAMME

**FRIDAY, 20.2.2026.**

#### **14:30 Welcome and Introductions**

**14:40-15:50 Section 1.**

**Moderator Martina Bašić Koretić**

<b>Z. MARUŠIĆ</b>	Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181/CompassHER2 pCR trial
<b>M. JAZVIĆ</b>	Prognostic Markers in Residual Tumors after Neoadjuvant Chemotherapy (NACT) for Early Triple-Negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B trials
<b>S. PLEŠTINA</b>	Effect of Adjuvant Carboplatin Intensified Chemotherapy versus Standard Chemotherapy on Survival in Women with High-Risk Early-Stage Triple-Negative Breast Cancer (CITRINE): A Phase 3 Randomized Trial .
<b>J. FLAM</b>	Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial
<b>T. SILOVSKI</b>	Sacituzumab Govitecan vs Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07

The satellite symposium section is not a part of the official program  
of the Best of SABCS.

**15:50-16:20      Satellite Symposium: Eli Lilly**

The satellite symposium section is not a part of the official program  
of the Best of SABCS.

**16:20-16:50      Satellite Symposium: Novartis**

**16:50-17:20 Coffee break**

The satellite symposium section is not a part of the official program  
of the Best of SABCS.

**17:20-17:50      Satellite Symposium: Roche**

**17:50-18:50      Section 2.**

**Moderator    Marijana Jazvić**

**A. STRIKIĆ**      Efficacy Analysis of the Randomized Phase III DETECT Trial:  
Treatment De- escalation by Omission of Chemotherapy and the  
Effect of Adding Ribociclib in HER2 positive and Hormone Positive  
Metastatic Breast Cancer

**M. BAN**      Clinical and biomarker subgroup analysis of evERA Breast Cancer:  
A Phase III trial of giredestrant plus everolimus in patients with  
estrogen receptor-positive, HER2-negative advanced breast  
cancer previously treated with a CDK4/6 inhibitor.

**J. CORTES** Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III IldERA Breast Cancer trial.

**N. ŠARIĆ** Optimizing De-escalation in Low-Risk HR+ Early-Stage Breast Cancer Radiation therapy or endocrine therapy: Which one to omit

## 18:50 End of program

---

**SATURDAY, 21.2.2026.**

**9:00-10:00** **Section 3.**

**Moderator** **Željko Soldić**

**S. TOMIĆ** HER2 low/ultralow: what the pathologist sees

**B. PETRIĆ MIŠE** DESTINY-Breast11 safety: neoadjuvant trastuzumab deruxtecan(T-DXd) alone or followed by paclitaxel + trastuzumab +pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer

**A. BUDISAVLJEVIĆ** Trastuzumab deruxtecan vs trastuzumab emtansine in pts with high risk HER2+ primary breast cancer with residual disease after neoadj th: interim analysis of Destiny -Breast 05.

**N. DEDIĆ PLAVETIĆ** HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

**M. PRUTKI** Effect of preoperative breast MRI Staging on Local regional recurrence ( LRR ) in early stage Breast Cancer: ALLiance AO11104/ACRIN6694

**The satellite symposium section is not a part of the official program  
of the Best of SABCS.**

**10:00-10:30      Satellite Symposium Novartis**

**The satellite symposium section is not a part of the official program  
of the Best of SABCS.**

**10:30-11:00      Satellite Symposium Eli Lilly**

**11:00-11:20 Coffee break**

**11:20-12:35 Section 4.**

**Moderator      Sanda Smuđ Orehovec**

**I. MILAS**      Omission of sentinel lymph node biopsy in clinically T1-2N0 breast cancer patients treated with breast- conserving therapy: results of the Dutch BOOG2013-08 randomized controlled after a median follow-up of 5 years

**A. DUJMOVIĆ**      More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy-primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R) study

**K. ANTUNAC**      Advances in breast radiotherapy: Less is more!

**M. SOČE**      Should we irradiate the IM Nodes: Settling the Issue

**T. MLINARIĆ KOPRIVANAC**

Repeat breast conservation with re-irradiation: What is the data and how do we do it

**The satellite symposium section is not a part of the official program  
of the Best of SABCs.**

**12:35-13:55      Satellite Symposium: Pfizer**

**13:00-14:00    Lunch/Break**

**The satellite symposium section is not a part of the official program  
of the Best of SABCs.**

**14:00 – 14:45      Satellite Symposium Astra Zeneca**

**14:45-15:35    Section 5.**

**Moderator      Ingrid Belac Lovasić**

**I. BIONDIĆ**      Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

**D. HUIĆ** FDG-PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE ECOG-ACRIN EA1183

**P. SERTIĆ** Cardiotoxicity of breast cancer novel therapies

**J. JOVIĆ ZLATOVIĆ**

Impact of Immune Checkpoint Inhibition on Fertility in Young Women with Early Triple-Negative Breast Cancer receiving neoadjuvant Chemotherapy: A prospective Substudy of the NSABP B-59/GeparDouzeTrial

**15:35-16:25 CLINICAL CONTROVERSIES:**

**Management of the Axilla in Multidisciplinary Care**

**R. ŽIC** De-escalation of axillary surgery after NAC in clinically node positive patients

**K. ANTUNAC** De-Escalation of Regional Nodal Irradiation after NAC in Clinically Node Positive Patients

**16:25-16:45 Coffee break**

**16:45-17:25 Section 6. YEAR IN THE REVIEW**

**Moderator** **Eduard Vrdoljak**

**M. BAŠIĆ KORETIĆ** Early breast cancer

**E. VRDOLJAK** Advanced breast cancer

**17:25-17:40 WHAT WILL WE DO ON MONDAY MORNING?**

**17:40 Summary and Closing Remarks**

**17:45 End of the Symposium**



# SAN ANTONIO BREAST CANCER SYMPOSIUM®

---

